BioSpace News Archive

Cybrexa Therapeutics announced that new data for its lead compound, CBX-12, a first-in-class investigational PDC, will be presented at the 2023 American Society of Clinical Oncology Annual Meeting being held in Chicago on June 2-6.

Biotheryx, Inc. announced two poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2–6, 2023, in Chicago, Illinois and online.

Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer cell-based therapies, announced the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.

Bristol Myers Squibb announced first results from the Phase 3 COMMANDS study, an open-label, randomized trial evaluating Reblozyl® versus epoetin alfa, an erythropoiesis-stimulating agent, for the treatment of anemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes who require red blood cell transfusions and are ESA-naïve.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology Annual Meeting.

BeiGene announced the presentation of new data showcasing the range of BeiGene’s research expertise and the productivity of one of the industry’s largest research and development teams at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health announced that data from SWOG S1826 have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology Annual Meeting, to be held both in person in Chicago and online from June 2-6.

eMolecules, Inc., an industry leading chemical compound search-and-fulfillment platform for early discovery chemistry research, announced the acquisition of Specs Compound Handling B.V..

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, shared interim results from an ongoing Phase 1/2 trial of AU-007, as detailed in the online publication of Abstract e14507 at the American Society of Clinical Oncology 2023 Annual Meeting.

CompuMed, Inc., a leader in providing diagnostic telemedicine has amended its certificate of incorporation to reduce the number of authorized shares from Twenty Million to Five Million.